CEO Kym Anthony was interviewed by the penny stock news and trends podcast, Uptick Newswire.
I think if people keep their eyes on the size of the prize, [they’ll see] the livestock market is in the billions of dollars; our share of that would be in the hundreds of millions if we roll out successfully. The human market is untouched. The companion animal market is also big. We’ve spent years proving it works; everyone agrees it works. Now is the time to roll it out commercially.
Click to play:
The interview covers all aspects of Avivagen’s business, including the problem of antibiotic resistance and how Avivagen is meeting this huge market demand; the companion animal product Vivamune Health and the company’s intention to focus on it in the coming year, and recent developments in proof-of-concept trials for humans trying to combat C. Difficile infection.